Objective: White Matter Hyperintensities (WMHs) are associated with cognitive decline in normative aging and Alzheimer's disease. However, the pathogenesis of cognitive decline in Parkinson's disease (PD) is not directly related to vascular causes, and therefore the role of WMHs in PD remains unclear. If WMH has a higher impact on cognitive decline in PD, vascular pathology should be assessed and treated with a higher priority in this population. Here we investigate whether WMH leads to increased cognitive decline in PD, and if these effects relate to cortical thinning Methods: To investigate the role of WMHs in PD, it is essential to study recentlydiagnosed/non-treated patients. De novo PD patients and age-matched controls (NPD=365,NControl=174) with FLAIR/T2-weighted scans at baseline were selected from Parkinson's Progression Markers Initiative (PPMI). WMHs and cortical thickness were measured to analyse the relationship between baseline WMHs and future cognitive decline (follow-up:4.09±1.14 years) and cortical thinning (follow-up:1.05±0.10 years).
Introduction:
While Parkinson's disease (PD) is typically characterized by motor symptoms, cognitive deficits occur in approximately 15% of patients in early drug-naïve stages 1 . Two decades after disease onset, this prevalence increases to over 80% 2 . Early mild cognitive impairment (MCI) is a strong predictor of later development of dementia 3, 4 , which is a key determinant of mortality and poorer quality of life in PD 5 . Cognitive impairment in PD is related to subcortical dysfunction in early stages, followed by cortical α-synuclein pathology and loss of neurotransmitters. However, it remains unclear to what degree white matter changes, historically described as leukoaraiosis 6 which are major signs of small-vessel disease (SVD) 7, 8 may contribute to cognitive dysfunction in PD.
White matter hyperintensities (WMHs) or leukoaraiosis are areas of increased signal in T2-weighted and FLAIR structural MRI. The neuropathologic correlates of WMHs are varied: loss of axons and glial cells, myelin rarefaction, spongiosis, perivascular demyelination, gliosis, subependymal glial accumulation and loss of the ependymal lining 8 . Despite the various findings, consensus exists regarding the association of WMHs and SVD 9 . The term SVD is mainly related to two etiologies: 1) age-related vascular disease, also referred as arteriolosclerosis, or vascular-risk-factor related SVD 10, 11 , and 2) cerebral amyloid angiopathy 12 . These two play a crucial role in stroke, dementia and aging, and could also be relevant in PD. Therefore, early detection of WMHs and treatment of cardiovascular risk factors could have a positive impact on cognitive decline in PD [13] [14] [15] [16] . In AD, WMHs have been extensively studied and strongly predict rapid cognitive decline in individuals with MCI 17, 18 . In PD, the pathogenic role of vascular risk factors is less clear 5 and results have been contradictory 16 . The WMHs might cause cognitive decline independent of PD, or the synergy between the two mechanisms may accelerate cognitive impairment 16 . Alternatively, the WMHs might aggravate the pathologic spread of misfolded α-synuclein or amyloid-β proteins. Of the few studies that have investigated WMHs and cognitive decline in PD, most are crosssectional, include patients that are on dopaminergic medication, and are typically from cohorts that are at later stages of disease [19] [20] [21] . Additionally, different groups implement different tests to assess cognition and many do not perform a comprehensive neuropsychological battery.
Capitalizing on the longitudinal assessment of cognitive abilities and imaging biomarkers in the multi-centre cohort of de novo PD patients from the Parkinson's Progression Markers Initiative 22 , we investigated the relationship between WMH burden and: 1) cognitive decline over time and 2) cortical grey matter changes over time (as indexed by cortical thinning) in early stages of PD.
Methods:
Patients: The Parkinson's Progression Markers Initiative (PPMI) is a longitudinal multi-site clinical study of de novo PD patients and age-matched healthy controls (HC) 22 of all participating sites and written informed consent was obtained from all participants before inclusion in the study. In the present study, we included all subjects that had either FLAIR or T2-weighted MR images at their baseline visit and had follow-up visits for at least one year after the baseline scan (NPD=365, NHC=174). All subjects were regularly assessed (yearly follow-ups, mean total follow-up period of 4.09±1. 14 semantic fluency test to detect cognitive decline (Table1). The executive function score is calculated as the sum of letter number sequencing and semantic fluency scores 23 . To validate the correlation between these two components, we verified their relationship in the PD population (r=0.56, p<0.0001). Procedures: All MR images were preprocessed using our standard pipeline 24 in three steps: noise reduction, intensity non-uniformity correction, and intensity normalization.
T2-weighted and FLAIR images were linearly co-registered to the T1-weighted images using a 6-parameter rigid registration. The T1-weighted images were first linearly and then nonlinearly registered to the standard template (MNI-ICBM-152). The WMHs were segmented using a previously validated automatic multi-modality segmentation technique in the native space of FLAIR or T2-weighted scans to avoid further blurring caused by resampling of the images 25, 26 . This technique uses a set of location and intensity features obtained from a library of manually segmented scans in combination with a random forest classifier to detect the WMHs in new images. The libraries used in this study were obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset since the T2-weighted and FLAIR sequences for the PPMI images follow the same acquisition protocol as ADNI. The quality of the registrations and segmentations was visually assessed and cases that did not pass this quality control were discarded (n=43). WMH load was defined as the volume (in cm 3 ) of all segmented WMH voxels in the standard space, i.e. the WMH volumes were corrected for total intracranial volume (ICV). All MRI processing and segmentation steps were blinded to clinical outcomes.
For voxel-wise analysis of WMHs, the WMH probability maps generated by the segmentation tool were nonlinearly transformed to the template space at 2×2×2 mm 3 resolution and blurred with a 3D Gaussian kernel with full width at half maximum of 5 mm to compensate for the variability caused by differences in voxel sizes in the native FLAIR and T2-weighted images. Rates of cognitive decline were calculated for subjects that had at least one-year follow-up information as the change of the score per year (NPD=365, NHC=174), using a linear regression between time and the score values at different time points along with an intercept term.
Only subjects with T1-weighted 3T MRI data at both initial/baseline visit and at a one-
year follow-up MRI were included for cortical thickness analysis (NTotal=155, see Table   1 ). Cortical models were generated using the CIVET 2.1 preprocessing pipeline 27 
Statistical Analysis:
We tested two major hypotheses: (1) greater WMH load will lead to more extensive and faster decline in cognition of the PD patients (2) patients with a higher WMH load (WMHL) will show more cortical thinning in their follow-up visit after one year.
Survival analysis was used to investigate the relationship between WMH burden and decline in cognition. It has been previously shown that a threshold of WMHs should be present before cognitive deficits are observed 28, 29 . The question of interest was whether there is a significant difference between the cognitive survival curves of subjects (normal controls and PD patients) with low versus high WMHL. The threshold for differentiating between high and low WMHL was set at 5 cm 3 (median value, 0.7% of WM volume, 0.27% of brain volume). Similar to previous studies [30] [31] [32] [33] Gaussian random field theory with a threshold of p<0.05 37 . Similar to the survival analysis, the threshold for differentiating between high and low WMHL was 5 cm 3 .
Observed differences in cortical thickness were then correlated to cognitive measures using Pearson partial correlations correcting for age. and 56% (95 CI=0.45-0.67) in controls, respectively (NPD-Low=186, NPD-High=174, NHC-Low=79, NHC-High=83). In PD, the high WMHL cohort experienced a significantly lower survival rate than the low WMHL cohort (χ 2 =30.9, p<0.00001, hazard ratio= 2.42).
Results
There was no high vs low difference in controls (χ 2 =2.5, p=0.11, hazard ratio= 1.52).
Furthermore, PD patients showed significantly lower survival rate compared to controls in the high WMHL group (χ 2 =6.7, p=0.009, hazard ratio=1.58) while the survival rate was not significantly different between two groups in low WMHL group (χ 2 =0.1, p = 0.8, hazard ratio=1.0). Similar results were obtained with a threshold of 10 cm 3 and 1-4 point drops in MoCA, suggesting that WMH load-based dichotomization is sensitive to a range in the cognitive decline as measured by MoCA. 
Mixed-Effects Modelling:
The mixed-effects modelling results based on age, baseline WMH, and their interaction ( 
Cortical Thickness:
Mean whole-brain cortical thickness decreased significantly among PD patients with both low (t1 = 3.3177mm ± 0.0993; t2 = 3.3087mm ± 0.1082) and high (t1 = 3.2932mm ± 0.0996; t2 = 3.2786mm ± 0.0966) WMH at baseline. Among PD patients, baseline WMH load did not correlate with whole-brain cortical thickness at baseline (r=-0.09, 
Voxel-wise Analysis:
Within the PD cohort, significant voxel-wise correlations were observed between WMH localization maps and the slope of MoCA and Benton scores, corrected for multiple comparisons using false discovery rate (FDR) adjustment and controlled for age and modality (Fig. 4) . The significant regions include voxels in all lobes: frontal, temporal, parietal, occipital, and also insular subcortical WM bilaterally. No significant associations were found for the HC cohort. No significant associations were found for HVLT and Executive Function scores in the PD cohort. No significant differences were observed between the baseline voxel-wise WMH maps of PD and HC cohorts after FDR correction. 
Discussion:
High WMHL PD patients experienced significantly higher decline than i) low WMHL PD patients and ii) high WMHL control subjects. Additionally, WMHL was significantly associated with whole-brain cortical thinning after only one-year follow-up in PD patients, but not in controls. Moreover, PD patients with a high WMHL at baseline showed significant cortical thinning of a frontal cluster compared to those with low WMHL. Taken together, these findings suggest that measures of WMHL in de novo PD patients can predict later cognitive decline, even in patients exhibiting no cognitive symptoms at baseline.
As with previous studies 38 , cross-sectional WMHL at baseline in early PD was not significantly associated with baseline cognitive performance. Rather, WMHL at baseline was associated with future cognitive deterioration across multiple cognitive domains including visuospatial, memory, and global cognition corrected for age. This suggests that we can extend previous work on later stages of PD, where WMH burden was significantly associated with conversion to dementia in patients with MCI 39, 40 , to the earliest stages of the disease. In line with these findings, post-mortem studies have
shown that vascular lesions are common in idiopathic PD (Lewy body disease of the brainstem type) 41 .
MoCA has been validated as a sensitive measure for detecting and monitoring cognitive change over time 34 . Controlling for age, MoCA decline was significantly correlated with baseline WMHL in the PD cohort, but not in controls. Additionally, PD subjects with high WMHLs were more likely to experience a 2-point drop in MoCA than (i) the low WMHL PD and (ii) the high WMHL HC subjects, as evaluated by the survival analysis.
The driver for cognitive decline in controls and PD appear to differ in that the former is largely driven by age, while the latter is affected by both advancing age and greater baseline WMH load.
While the literature on PD and WMH is scarce, there has been substantial progress in understanding the relationship between WMHs and cognitive impairment/dementia in AD, especially in the context of amyloid pathology. WMHs associated with vascular risk factors (e.g., hypoperfusion and inflammation) are thought to precede Aβ aggregation. Previous work found significant associations between baseline WMHs and later progression of amyloid load 42 . This further supports the hypothesis of a chain of events; namely WMH impairs clearance of amyloid, which builds up and contributes to cognitive impairment and AD symptoms. While amyloid deposition strongly predicts progression to AD, WMH burden can provide additional independent information to this prediction 43 , suggesting that WMH is not solely related to amyloid pathology, but can directly impact cognitive impairment. Whether a similar interaction between vascular lesions and α-synuclein formation or deposition occurs in PD remains unclear.
WMH burden can also precede irreversible neurological damage as indexed by cortical atrophy. Previous studies have found higher WMHL to be correlated with lower cortical thickness in frontotemporal regions which in turn are related to cognitive decline 44 .
Cortical thinning caused by direct or indirect effects of WMHs (tract-specific damage) might lead to cognitive decline and eventually dementia. Cortical thickness might be a sensitive measurement to detect regional grey matter micro-changes that are missed by conventional voxel-based techniques at the earlier stages of the neurodegeneration due to partial volume effect 45, 46 . While we observed whole-brain cortical thinning among all PD patients, those with high WMH load showed greater cortical thinning of a frontal cluster, mostly encompassing the right dorsolateral prefrontal cortex (rDLPFC) which was further associated with decline in memory performance in HVLT over the one-year period. This is consistent with previous studies that have found significant associations between rDLPFC and HVLT scores 47, 48 . Our results suggest that cortical changes in early PD are potentially moderated by WMH load, and might in turn presage cognitive decline.
Regardless of etiology, prevention and treatment of vascular risk factors associated with
WMHs is a promising avenue to slow down cognitive deterioration, especially in de novo PD patients who are largely cognitively asymptomatic. The classical and most explored strategy regarding reduction of vascular disease risk and WMHs has been to control hypertension, which subsequently reduces the risk of cognitive deterioration 10, 11, 49 . In a randomized trial, active lowering of blood pressure was shown to stop or lower the progression of WMHs in patients with cerebrovascular disease over 3 years of follow-up 13 . In the present cohort, we observed an association between WMH load and (systolic-diastolic) blood pressure for both PDs and controls (p<0.001).
However, there is also evidence linking WMHs and dementia in PD to orthostatic hypotension, a common occurrence in PD which can be aggravated with antihypertensive medication, especially as the disease progresses 50 From a practical standpoint, WMHs can be quantified reliably and non-invasively on large samples and can be measured as a continuous trait, thus providing increased statistical power to detect potential associations 11 . The image processing and WMH segmentation pipelines used in this study have been designed to process data from multi-center studies, are able to control biases due to multi-site MRI scanning (i.e. differences in acquisition parameters), and have been previously applied successfully to a number of multi-site projects [51] [52] [53] . The WMH segmentation pipeline has been trained and extensively validated on data from multiple scanners and different acquisition parameters to ensure inter-site and inter-scanner generalizability 26 .
We acknowledge there are limitations to the present study. First, though their differences were accounted for in our analysis, segmentations were based on either T2weighted or FLAIR images, of which the latter has the better contrast for detecting WMHs. Second, subjects had these scans only at their baseline visit; therefore, we were not able to study the longitudinal changes of WMHs. Future studies investigating WMHs in PD during prodromal and pre-clinical stages are warranted, though there are inherent constraints in recruiting such a cohort. Also, the population under study included relatively cognitively intact individuals (none of the subjects met criteria for dementia), limiting the ability to detect important contributors. Longer follow-ups might further increase the observed differences. One potential confounding factor could be PD medication. However, previous studies have found no significant difference between PD patients on PD medications and PD patients off medications in MoCA and several other cognitive tasks 54 . Similarly, we found no relationship between MoCA and medication in PD patients. Another limitation is that we cannot identify the underlying mechanism.
The WMHs might cause cognitive decline independent of PD, however the synergy between the two mechanisms may accelerate the cognitive decline. Alternatively, the WMHs might aggravate the pathologic spread of misfolded α-synuclein proteins in PD.
Another possibility is that WMHs in PD may promote amyloid propagation, similar to AD.
In conclusion, our findings suggest that WMH burden is an important predictor of subsequent acceleration in cortical thinning and cognitive decline in early-stage de novo PD. Recognizing WMHs as early indicators of cognitive deficit, prior to onset of MCI or dementia, provides an opportunity for timely interventions 22, 51 . 
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